Valuation: SanBio Company Limited

Market Cap 73.84B 467M 419M 387M 351M 655M 44.45B 663M 4.63B 1.84B 23.26B 1.75B 1.71B P/E 2027 *
-15.8x
P/E 2028 * -15.6x
Enterprise Value 66.38B 420M 376M 348M 315M 589M 39.96B 596M 4.16B 1.66B 20.91B 1.57B 1.54B EV / Sales 2027 *
157x
EV / Sales 2028 * 29.1x
Free-Float
75.37%
Yield 2027 *
-
Yield 2028 * 0.04%
1 day-1.16%
1 week+3.66%
Current month-3.01%
1 month+1.96%
3 months+3.89%
6 months-50.13%
Current year-44.67%
1 week 885
Extreme 885
984
1 month 869
Extreme 869
1,081
Current year 858
Extreme 858
2,691
1 year 858
Extreme 858
2,933
3 years 380
Extreme 380
3,990
5 years 380
Extreme 380
3,990
10 years 380
Extreme 380
12,730
Manager TitleAgeSince
Chief Executive Officer 59 2013-02-26
Chief Tech/Sci/R&D Officer - -
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 58 2013-02-26
Director/Board Member 59 2013-02-26
Director/Board Member 69 2013-02-28
Change 5-day change 1-year change 3-year change Capi.($)
-1.06%+3.66%-65.62%+123.68% 460M
+0.65%-3.36%+36.98%+60.50% 63.48B
+1.76%+1.27%+11.82%+81.21% 54.55B
-0.94%+0.99%+10.45%+100.19% 53.59B
+2.76%+0.87%+27.92%+55.07% 44.75B
+2.00%-3.39%+17.83%+119.04% 41.62B
+1.34%-2.86%+224.43%+914.08% 39.91B
+0.64%-3.95%+11.15%+45.57% 32.47B
+29.06%+47.63%+107.12%+92.73% 26.7B
-2.50%+0.75%+24.66%-9.70% 23.36B
Average +3.46%+0.16%+40.67%+158.24% 38.09B
Weighted average by Cap. +2.91%+0.19%+47.97%+161.01%

Financials

2027 *2028 *
Net sales 423M 2.68M 2.4M 2.22M 2.01M 3.75M 255M 3.8M 26.53M 10.57M 133M 10.04M 9.83M 2.42B 15.29M 13.72M 12.69M 11.49M 21.47M 1.46B 21.73M 152M 60.42M 762M 57.39M 56.18M
Net income -4.75B -30.04M -26.95M -24.92M -22.56M -42.16M -2.86B -42.67M -298M -119M -1.5B -113M -110M -4.87B -30.8M -27.64M -25.55M -23.14M -43.23M -2.93B -43.76M -306M -122M -1.54B -116M -113M
Net Debt -7.46B -47.18M -42.33M -39.14M -35.44M -66.22M -4.49B -67.02M -468M -186M -2.35B -177M -173M -3.37B -21.31M -19.12M -17.68M -16.01M -29.91M -2.03B -30.28M -211M -84.19M -1.06B -79.98M -78.29M
Projected Income Statement - Annual - SanBio Company Limited
Logo SanBio Company Limited
SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).
Employees
33
Date Price Change Volume
26-10-28 JP¥936.00 -1.06% 414,000
26-10-28 JP¥946.00 +1.72% 998,900
26-10-27 JP¥930.00 +3.33% 579,700
26-10-26 JP¥900.00 -2.60% 865,800
26-10-23 JP¥924.00 +2.44% 1,416,400
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - SanBio Company Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
946.00JPY
Average target price
1,400.00JPY
Spread / Average Target
+47.99%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - SanBio Company Limited
  1. Stock Market
  2. Stocks
  3. 4592 Stock